Growth • Lantheus Holdings
LNTH
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
34,6%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
54,1%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
58,1%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
40,7%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
37%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
46,6%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!